AbbVie
ABBVAbbVie is a global, research-based biopharmaceutical company focused on developing and marketing advanced therapies for complex and serious diseases.
Earnings
Next report
Oct 30, 2026 (in 2 months)Financials
Q2 2026Income statement
Valuation & ratios
Segments
By product
Competitors
By market cap
By revenue growth
Profile
AbbVie is a global, research-based biopharmaceutical company focused on developing and marketing advanced therapies for complex and serious diseases. The company maintains leadership positions in several high-growth therapeutic areas including immunology, oncology, neuroscience, and aesthetics. Its value proposition is centered on clinical innovation and a diversified portfolio of proprietary medicines that address significant unmet medical needs.
A global leader in immunology and aesthetics with a dominant market share in biologic therapies, currently managing the transition of its legacy blockbuster portfolio toward newer growth assets.
FAQ
- What is AbbVie's market cap?
- AbbVie (ABBV) has a market capitalization of $464.58B and trades on NYSE.
- What is AbbVie's revenue and profitability?
- AbbVie generated $64.4B in trailing twelve-month revenue with net income of $6.3B, representing a net margin of 9.8%. Gross margin stands at 71.5%. These figures are based on the Q2 2026 filing.
- Who are AbbVie's competitors?
- AbbVie's key competitors include Pfizer, Johnson & Johnson, Amgen, and others. These companies compete in similar markets and product categories.
- Who does AbbVie partner with?
- AbbVie's notable partners include GSK, Eisai, Genmab.
- What subsidiaries does AbbVie have?
- AbbVie's subsidiaries include Allergan, ImmunoGen.
- Where is AbbVie headquartered?
- AbbVie is headquartered in United States of America and employs approximately 50,000 people. It has been publicly traded since 2012.
